Saphenous vein graft disease.

Area of Science:

• Cardiovascular Surgery
• Interventional Cardiology
• Vascular Biology

Background:

• Saphenous vein graft (SVG) disease remains a significant challenge after coronary artery bypass grafting (CABG).
• SVG disease progresses through distinct phases: thrombosis, intimal hyperplasia, and atherosclerosis, leading to recurrent ischemia.
• Repeat operations carry high mortality/morbidity, while percutaneous treatments face procedural and long-term complications.

Purpose of the Study:

• To review the pathogenesis of SVG disease.
• To discuss current and emerging therapeutic options for managing SVG disease.
• To highlight challenges and potential solutions in treating SVG disease.

Main Methods:

• Literature review of pathogenesis and therapeutic strategies for SVG disease.
• Analysis of complications associated with repeat operations and percutaneous interventions.
• Evaluation of novel approaches, including drug-eluting stents and distal protection devices.

Main Results:

• SVG disease involves thrombosis, intimal hyperplasia, and atherosclerosis, resulting in poor long-term patency.
• Percutaneous treatment is hindered by distal embolization, no-reflow, myocardial infarction, and restenosis.
• Distal protection devices offer some benefit; drug-eluting stents show promise for reducing restenosis.

Conclusions:

• Effective management of SVG disease requires addressing its complex pathogenesis and multifactorial complications.
• Novel therapies like drug-eluting stents represent a significant advancement in improving outcomes for SVG disease.
• Further research is needed to optimize treatment strategies and improve long-term graft patency.